70855-59-3

Usage

Uses

Used in Pharmaceutical Applications:
1H-Inden-5-ol,2,3-dihydro-3,6-dimethyl-1-(2-methyl-1-propenyl)-,(1R,3S)-rel-(+)is used as a building block in pharmaceutical applications due to its unique structure and stereochemistry. Its dihydro-indenol framework and chiral centers make it a promising candidate for the development of new drugs and therapeutic agents.
Used in Organic Synthesis:
In the field of organic synthesis, 1H-Inden-5-ol,2,3-dihydro-3,6-dimethyl-1-(2-methyl-1-propenyl)-,(1R,3S)-rel-(+)serves as a valuable intermediate for the synthesis of more complex organic molecules. Its specific stereochemistry and functional groups can be utilized in various synthetic routes to create a wide range of compounds.
Used in Fragrance and Flavor Formulations:
Due to its unique structure and stereochemistry, 1H-Inden-5-ol,2,3-dihydro-3,6-dimethyl-1-(2-methyl-1-propenyl)-,(1R,3S)-rel-(+)may have potential applications in the fragrance and flavor industry. Its chiral nature could contribute to distinct olfactory and gustatory properties, making it a candidate for the development of novel scents and tastes.
Used in Chiral Chemical Research:
The specific stereochemistry of 1H-Inden-5-ol,2,3-dihydro-3,6-dimethyl-1-(2-methyl-1-propenyl)-,(1R,3S)-rel-(+)makes it an interesting subject for research in the field of chiral chemistry. Studying its properties and interactions can provide insights into the role of stereochemistry in chemical reactions and the development of enantioselective processes.

Upstream product

• 75-16-1 methylmagnesium bromide 
• 107-86-8 3,3-dimethyl acrylaldehyde 
• 39724-80-6 ar-E-Atlantone 
• 122-00-9 para-methylacetophenone 
• 113283-35-5 2-Hydroxy-2-(p-tolyl)-6-methylhept-5-en-4-one 
• 141-79-7 4-methyl-pent-3-en-2-one 
• 1141-54-4 (R)-2-methyl-6-(4-methylphenyl)-2-hepten-4-one 
• 1131235-78-3 (+)-(1S,3R)-5-methoxy-3,6-dimethyl-1-(2-methylprop-1-enyl)-1H-indane 

Relevant academic research and scientific papers

Asymmetric Hydroarylation of Enones via Nickel-Catalyzed 5- Endo-Trig Cyclization

A nickel-catalyzed reductive cyclization of enones affords a wide array of indanones in high enantiomeric induction. The reaction is featured with an unprecedented broad scope of substrates. The versatility of the new method is demonstrated in several short stereoselective syntheses of medically valuable (R)-tolterodine, parent and deuterated (+)-indatraline, and an antitumor natural product, (+)-multisianthol. In comparison, these compounds cannot be prepared satisfactorily via analogous processes catalyzed by palladium.

Lewis Base-Catalyzed Enantioselective Conjugate Reduction of β,β-Disubstituted α,β-Unsaturated Ketones with Trichlorosilane: E/ Z-Isomerization, Regioselectivity, and Synthetic Applications

The chiral bisphosphine dioxide-catalyzed asymmetric conjugate reduction of acyclic β,β-disubstituted α,β-unsaturated ketones with trichlorosilane affords saturated ketones having a stereogenic carbon center at the carbonyl β-position with high enantioselectivities. Because the E/Z-isomerizations of enone substrates occur concomitantly, reduction products with the same absolute configurations are obtained from either (E)- or (Z)-enones. Conjugate reduction is accelerated in the presence of an electron-rich aryl group at the β-position of the enone owing to its carbocation-stabilizing ability. Computational studies were also conducted in order to elucidate the origin of the observed enantioselectivity. The regio- and enantioselective reductions of dienones were realized and applied to the syntheses of ar-turmerone, turmeronol A, mutisianthol, and jungianol, which are optically active sesquiterpenes.

(+)- And (-)-mutisianthol: First total synthesis, absolute configuration, and antitumor activity

The first synthesis of the natural product (+)-mutisianthol was accomplished in 11 steps and in 21% overall yield from 2-methylanisole. The synthesis of its enantiomer was also performed in a similar overall yield. The absolute configuration of the sesquiterpene (+)-mutisianthol was assigned as (15,37?). Key steps in the route are the asymmetric hydrogenation of a nonfunctionalized olefin using chiral iridium catalysts and the ring contraction of 1,2-dihydronaphthalenes using thallium(III) or iodine(III). The target molecules show moderate activity against the human tumor cell lines SF-295, HCT-8, and MDA-MB-435.